The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
During the 2023 Society of Hematologic Oncology Congress (SOHO), the ALL Hub spoke to Bijal Shah, Moffitt Cancer Center, Tampa, US. We asked, What are the challenges of sequencing immunotherapies in adults with acute lymphoblastic leukemia (ALL)?
What are the challenges of sequencing immunotherapies in adults with ALL?
First, Shah discussed the sequencing approach with immunotherapies in B-cell ALL, including the use of blinatumomab in newly diagnosed adult patients; this is based on positive results from the ECOG ACRIN E1910 trial. The results indicated its potential future use as a component of a multi-agent therapy for most adult patients. He then highlighted the promising data on inotuzumab ozogamicin (InO), highlighting the safety and clinical benefit of mini-CVD plus InO in older adults with B-ALL.
For the remainder of the discussion, Shah talks about the use of chimeric antigen receptor (CAR) T-cell therapy, including how prior exposures to either blinatumomab, InO, or both, can affect outcomes. He also discusses the use of immunotherapies as salvage after CAR T-cell therapy failure, and the incorporation of CAR T-cell therapy into earlier lines of therapy. To close, he emphasises the need for caution when sequencing immunotherapies, given most patients with refractory disease have a high disease burden. Currently, there are several ongoing studies investigating novel immunotherapies aiming to shift the treatment paradigm, prolong survival, and cure a higher proportion of patients with ALL.
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?